AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.
Technavio's analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2025.
In 2019, the market size of Acute Ischemic Stroke Therapeutics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of 0.021 from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Acute Ischemic Stroke Therapeutics.

This report studies the global market size of Acute Ischemic Stroke Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Acute Ischemic Stroke Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Bayer
Boehringer Ingelheim
Roche
Sanofi
Biogen
Daiichi Sankyo
Pfizer
...

Market Segment by Product Type
Thrombolytic Therapeutics
Antihypertensive Therapeutics
Antiplatelet Therapeutics
Anticoagulants

Market Segment by Application
Hospitals
Ambulatory Surgical Center
Diagnostic Centers

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Acute Ischemic Stroke Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Acute Ischemic Stroke Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Acute Ischemic Stroke Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025